Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myasthenia gravis. A survey.

H J Oosterhuis

    Clinical Neurology and Neurosurgery
    |January 1, 1981
    PubMed
    Summary

    Myasthenia gravis is an autoimmune disorder causing muscle weakness due to reduced acetylcholine receptors. Treatments like anticholinesterases and thymectomy offer partial to excellent benefits for patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Physical examination--measurement of muscle strength].

    Nederlands tijdschrift voor geneeskunde·2001
    Same author

    Myasthenia gravis on the Dutch antilles: an epidemiological study.

    Clinical neurology and neurosurgery·2001
    Same author

    [Physical diagnosis--signs of lumbosacral irritation].

    Nederlands tijdschrift voor geneeskunde·1999
    Same author

    [A series of articles on the usefulness and uselessness of physical diagnostics; comment].

    Nederlands tijdschrift voor geneeskunde·1999
    Same author

    [Favorable results of plasmapheresis in severe myasthenia gravis].

    Nederlands tijdschrift voor geneeskunde·1997
    Same author

    Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.

    Journal of neurology·1997

    Area of Science:

    • Neurology
    • Immunology
    • Pathophysiology

    Background:

    • Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
    • It leads to fluctuating muscle weakness, particularly affecting cranial nerves.
    • Pathophysiology involves loss of postsynaptic acetylcholine receptors (AChRs) and autoantibodies against AChRs.

    Purpose of the Study:

    • To review the pathophysiology, pathogenesis, and therapeutic outcomes of myasthenia gravis.
    • To highlight the role of the thymus in MG development.
    • To summarize current treatment strategies and their efficacy.

    Main Methods:

    • Review of existing literature on myasthenia gravis.
    • Analysis of pathophysiological mechanisms, including receptor loss and autoantibody presence.
    • Evaluation of clinical data on disease course and treatment responses.

    Main Results:

    • 80-90% of patients have detectable anti-AChR antibodies.
    • Experimental autoimmune myasthenia gravis (EAMG) models mimic human MG.
    • Thymus abnormalities (tumors, germinal centers) are implicated in pathogenesis.
    • Anticholinesterase therapy provides partial benefit.
    • Thymectomy improves outcomes in a significant portion of patients, especially younger ones without thymoma.
    • Immunosuppressive drugs and prednisone improve prognosis for severe cases.

    Conclusions:

    • Myasthenia gravis is a specific autoimmune disease targeting acetylcholine receptors.
    • The thymus plays a critical role in MG pathogenesis, though the exact mechanism remains unclear.
    • Therapeutic interventions, including anticholinesterases, thymectomy, and immunosuppression, offer varying degrees of benefit and have improved patient prognosis.

    Related Experiment Videos